Trial Profile
A Retrospective, Single-centre, Real-world study to evaluate the safety and efficacy of sodium-glucose co-transporter 2 inhibitor (SGLT2) in patients with Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 20 Apr 2017 New trial record
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society